Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-01-16

FDA Approved: EDARBI — Supplemental Application (Azurity Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for EDARBI (azilsartan medoxomil) submitted by Azurity Pharmaceuticals, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Edarbi (azilsartan medoxomil)

Snippet

SUPPL AP for EDARBI (AZILSARTAN KAMEDOXOMIL)